Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.49 |
| ▸ | ESR1 | P03372 | 5/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.46 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591812 | 0.83 | ERN1 (0.46) | ERN1ESR1ESR2MEN1KMT2A | |
| SCHEMBL30740933 | 0.83 | ERN1 (0.46) | ERN1ESR1ESR2MEN1KMT2A | |
| SCHEMBL29828302 | 0.81 | ERN1 (0.46) | ERN1ESR1ESR2 | |
| SCHEMBL23480395 | 0.79 | ALOX5AP (0.42) | ERN1MEN1KMT2A | |
| SCHEMBL21199864 | 0.79 | ERN1 (0.45) | ERN1ESR1ESR2CYP17A1CYP11B1 | |
| SCHEMBL10041729 | 0.79 | TDP1 (0.50) | ERN1ESR1ESR2GSTP1ALOX5 | |
| SCHEMBL13350235 | 0.79 | ERN1 (0.52) | ERN1ESR1ESR2GSTP1ALOX5 | |
| SCHEMBL19153689 | 0.78 | CYP1A2 (0.50) | ERN1ESR1ESR2GSTP1CYP1A2 | |
| SCHEMBL2774294 | 0.77 | KIF11 (0.44) | ERN1ESR1ESR2MEN1KMT2A | |
| SCHEMBL13830984 | 0.77 | LMNA (0.46) | ERN1CYP1A2CYP2A6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1762605-B1 | Naphthalene compound with terminal hydrogen, liquid crystal composition including the compound, and LCD device including the liquid crystal composition | CHISSO PETROCHEMICAL CORP (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-7790915-B2 | Naphthalene compound with terminal hydrogen, liquid crystal composition including the compound, and LCD device including the liquid crystal composition | CHISSO PETROCHEMICAL CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| EP-1762605-A1 | Naphthalene compound with terminal hydrogen, liquid crystal composition including the compound, and LCD device including the liquid crystal composition | Chisso Petrochemial Corporation (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20070051919-A1 | NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION | CHISSO PETROCHEMICAL CORPORATION (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070051919-A1 | NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION | LEF1, CFD, FOXO1 | ERN1 1633/4885ESR1 1826/4885ESR2 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.